Market closedNon-fractional

Travere Therapeutics/TVTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Travere Therapeutics

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Ticker

TVTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

380

TVTX Metrics

BasicAdvanced
$604M
Market cap
-
P/E ratio
-$2.11
EPS
0.78
Beta
-
Dividend rate
$604M
0.78
2.777
2.699
538.645
545.444
-37.07%
-35.53%
-315.89%
3.901
8.17
-22.33
-1.794
69.52%
-52.59%
-7.69%
-21.84%

What the Analysts think about TVTX

Analyst Ratings

Majority rating from 16 analysts.
Buy

TVTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-329.29% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$41M
-8.22%
Net income
-$136M
50.94%
Profit margin
-329.29%
64.46%

TVTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 77.61%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.13
$1.97
-$1.18
-$1.76
-
Expected
-$1.14
-$0.14
-$1.27
-$0.99
-$0.89
Surprise
-0.95%
-1,480.26%
-7.27%
77.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Travere Therapeutics stock?

Travere Therapeutics (TVTX) has a market cap of $604M as of July 05, 2024.

What is the P/E ratio for Travere Therapeutics stock?

The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of July 05, 2024.

Does Travere Therapeutics stock pay dividends?

No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next Travere Therapeutics dividend payment date?

Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Travere Therapeutics?

Travere Therapeutics (TVTX) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Travere Therapeutics stock

Buy or sell Travere Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing